Insights into public preferences for pharmaceutical funding

Whitty, Jennifer A. ORCID: https://orcid.org/0000-0002-5886-1933, Rundle‐Thiele, Sharyn R. and Scuffham, Paul A. (2008) Insights into public preferences for pharmaceutical funding. International Journal of Pharmaceutical and Healthcare Marketing, 2 (3). pp. 216-234. ISSN 1750-6123

Full text not available from this repository. (Request a copy)

Abstract

Purpose – Taxes are used to subsidise the public use of pharmaceuticals in some countries. This paper seeks to quantify criteria considered important by the Australian public for allocating resources for pharmaceuticals. Design/methodology/approach – A discrete choice experiment (DCE) was administered to two samples of adults in Australia. A forced choice design was used in a pilot study, but an opt‐out option was included in the main study to avoid forcing choice. Data were analysed using multinomial logit. Findings – For the levels and units presented in the DCE, quality of life (QoL) after treatment was the most important attribute in both the pilot and main studies, followed by survival after treatment and the chance of success for a given pharmaceutical. Cost to the government was of little importance in the pilot study, but was of importance in the main study. Practical implications – By understanding public preferences, marketers can tailor pharmaceutical offerings that appeal to the public and to relevant pharmaceutical funding bodies when making submissions, thus increasing the likelihood of receiving public funding support. Understanding public preferences allows public policy‐makers to direct resources towards those medical technologies which are likely to give the greatest overall societal benefit. Originality/value – This study shows the simultaneous importance of survival, QoL, chance of success and cost to public preferences for pharmaceutical funding. Cost (tax) signals suggest the public are willing to limit the amount they expect the government to pay for effective pharmaceuticals.

Item Type: Article
Uncontrolled Keywords: pharmaceutical products,australia,health services,behaviour
Faculty \ School: Faculty of Medicine and Health Sciences > Norwich Medical School
UEA Research Groups: Faculty of Medicine and Health Sciences > Research Groups > Health Economics
Faculty of Medicine and Health Sciences > Research Groups > Respiratory and Airways Group
Faculty of Medicine and Health Sciences > Research Groups > Health Services and Primary Care
Faculty of Medicine and Health Sciences > Research Groups > Public Health and Health Services Research
Depositing User: Pure Connector
Date Deposited: 27 Apr 2016 16:01
Last Modified: 26 Jan 2023 10:30
URI: https://ueaeprints.uea.ac.uk/id/eprint/58453
DOI: 10.1108/17506120810903980

Actions (login required)

View Item View Item